Independent research summaries for commonly discussed peptides. All entries are for educational purposes only.
A small molecule (technically not a peptide) studied as an NNMT inhibitor for metabolic and adipose-tissue applications.
An AMPK activator (not technically a peptide) studied for "exercise-mimetic" metabolic effects on endurance and fat oxidation.
A modified fragment of human growth hormone (the C-terminal 176–191 region) studied for fat metabolism without GH's other effects.
A three-peptide fat-loss focused blend combining AOD-9604's lipolytic action with a GHRH/GHRP duo to elevate GH.
A research bioregulator marketed as a cognitive and mood-support peptide. Sparse formal research literature.
A proapoptotic peptidomimetic designed to selectively target adipose-tissue vasculature, originally studied in primate weight-loss models.
A non-erythropoietic erythropoietin analog studied for diabetic neuropathy, sarcoidosis-related small-fiber neuropathy, and tissue protection.
A research peptide studied for its potential role in tissue and gut repair.
A popular healing-stack blend pairing the two most-studied tissue-repair peptides into a single vial for simpler dosing.
A growth-hormone-releasing hormone analog studied for performance contexts.
A more potent GH blend than the Ipamorelin version, trading some selectivity for a larger GH pulse.
A long-acting GHRH analog modified with a drug affinity complex that binds albumin, extending half-life to roughly a week and producing sustained GH elevation.
A two-vial stack pairing long-acting CJC-1295 DAC (weekly) with daily Ipamorelin pulses.
The most popular GH-stimulation blend — GHRH analog plus selective GHRP, in a single vial.
A long-acting amylin analog studied as a monotherapy and in combination with semaglutide (CagriSema) for weight management.
A blend pairing the amylin analog Cagrilintide with the GLP-1 agonist Semaglutide for additive metabolic effects. Active clinical investigation.
A Khavinson bioregulator marketed for cartilage and connective-tissue support in age-related joint issues.
A complex mixture of low-molecular-weight peptides derived from pig brain proteins, used clinically in Europe and Asia for stroke recovery, traumatic brain injury, and Alzheimer's research.
A Khavinson tripeptide bioregulator marketed for respiratory and pulmonary tissue support.
A short bioregulator peptide from the Khavinson family, studied for cerebral cortex regulation and cognitive function in aging.
A neuropeptide first isolated from rabbit cerebral venous blood, studied for sleep regulation, stress modulation, and pain modulation.
A tetrapeptide (Ala-Glu-Asp-Gly) developed in Russia, studied for telomerase activation, melatonin regulation, and longevity effects in animal models.
A tetrapeptide studied in longevity research, often dosed in short cyclic protocols.
A senolytic peptide designed to disrupt FOXO4–p53 interaction, selectively triggering apoptosis of senescent cells.
A naturally occurring tripeptide–copper complex studied for skin remodeling, hair growth, and wound healing. Levels in human plasma decline with age.
An older-generation GHRP studied for robust GH release. More potent than ipamorelin but also raises cortisol and prolactin slightly.
A first-generation GHRP best known for potent appetite stimulation alongside GH release. Less selective than newer peptides.
A skin and tissue-focused blend combining the copper-peptide GHK-Cu with the BPC-157/TB-500 healing duo.
The body's primary intracellular antioxidant, used in IV and subcutaneous protocols for oxidative-stress reduction, skin lightening, and detoxification support.
A synthetic version of natural gonadotropin-releasing hormone, used clinically for HPG-axis testing and treatment of hypogonadism.
A natural hormone produced in pregnancy, used clinically for fertility, hypogonadism, and HPG-axis restart protocols.
Recombinant human growth hormone — the actual GH protein produced by E. coli or mammalian cell expression, used clinically for GH deficiency.
A mixture of LH and FSH used clinically for fertility, particularly in ovarian stimulation and spermatogenesis support.
A long-acting analog of insulin-like growth factor-1 with greatly extended half-life compared to native IGF-1, studied for muscle growth contexts.
A selective growth-hormone-releasing peptide often paired with CJC-1295.
A five-peptide blend layering anti-inflammatory, antimicrobial, and tissue-repair compounds in one vial.
A small tripeptide derived from the C-terminus of α-melanocyte-stimulating hormone, studied for anti-inflammatory effects in skin and gut.
A neuropeptide that regulates GnRH release from the hypothalamus, studied for puberty initiation, fertility, and HPG-axis support.
An amino-acid derivative essential for transporting long-chain fatty acids into mitochondria for oxidation. Used in both clinical deficiency and athletic contexts.
A naturally occurring antimicrobial peptide produced by human immune cells, studied for broad-spectrum antimicrobial activity, wound healing, and immunomodulation.
A Khavinson tetrapeptide bioregulator marketed for liver and pancreas function support.
A splice variant of IGF-1 produced locally in response to mechanical stress, studied for satellite-cell activation and localized muscle repair.
A mitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, exercise performance, and longevity.
A dual GLP-1 / glucagon receptor agonist developed in China, studied for weight loss and type-2 diabetes.
A non-selective melanocortin receptor agonist studied originally for tanning. Also produces libido and erectile effects via MC4R, separate from MC1R-driven tanning.
A central coenzyme involved in mitochondrial energy production and sirtuin activation, used in IV and subcutaneous protocols for energy, recovery, and longevity research.
A cognitive-stack blend pairing nootropic peptides (Selank, Semax) with BPC-157 for neuroprotective support.
A Khavinson tetrapeptide bioregulator marketed for hepatic, intestinal, and ovarian function support.
A 9-amino-acid neuropeptide produced in the hypothalamus, involved in social bonding, intimacy, lactation, and uterine contractions.
A synthetic analog of the spadin peptide, studied as a fast-acting antidepressant via TREK-1 channel blockade.
A PEGylated variant of MGF with extended half-life, allowing systemic rather than purely local action.
A synthetic peptide containing an HDM-2 binding region of p53 fused to a membrane-residence sequence, studied in oncology research as a selective cancer-cell membrane-disrupter.
A melanocortin-receptor agonist approved for hypoactive sexual desire disorder in premenopausal women, also used off-label for libido in men.
A two-vial stack pairing PT-141 for libido with Melanotan II for tanning and additional libido effect.
A semi-synthetic polysaccharide studied for joint and connective-tissue conditions, particularly osteoarthritis and interstitial cystitis.
A Khavinson-family bioregulator targeting the pineal gland, studied for cognitive function, sleep, and circadian regulation.
A Khavinson bioregulator marketed for prostate-tissue support in age-related changes.
A triple agonist of GLP-1, GIP, and glucagon receptors in late-stage clinical trials. Phase 2 data showed ~24% body-weight loss at 48 weeks.
An experimental small-molecule ERR agonist (estrogen-related receptor) studied in mice as a potential exercise mimetic with weight-loss effects.
An octapeptide originally developed as a topical anti-wrinkle compound (cosmetic SNARE-protein modulator), more recently studied in research contexts for neurotransmitter modulation.
A cell-permeable tetrapeptide that targets cardiolipin in inner mitochondrial membranes, studied for mitochondrial dysfunction in aging, heart failure, and primary mitochondrial disease.
A research peptide studied for anxiolytic and cognitive effects, often intranasal.
A GLP-1 receptor agonist widely studied in metabolic and weight research.
A synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH) studied for nootropic, neuroprotective, and stroke-recovery effects.
An older GHRH analog and one of the first synthetic peptides used in clinical practice for GH-deficiency evaluation and treatment.
A dual GLP-1 / glucagon receptor agonist in clinical development, similar mechanism to mazdutide.
A synthetic version of thymosin beta-4 studied in injury and recovery research.
A two-vial stack version of the BPC-157 + TB-500 protocol — same combination as the blend, just with separate vials for individualized dosing.
A stabilized GHRH analog approved for HIV-associated lipodystrophy, widely studied for visceral-fat reduction.
A potent GH-stimulation blend combining the stabilized GHRH analog Tesamorelin with selective GHRP Ipamorelin.
A Khavinson bioregulator marketed for testicular tissue and male reproductive support.
A 28-amino-acid peptide isolated from the thymus, used clinically as an immune modulator for chronic hepatitis B/C, certain cancers, and immune deficiency.
A dual GIP/GLP-1 receptor agonist showing greater weight loss than GLP-1 monotherapy in head-to-head trials.
A three-peptide healing stack combining BPC-157 + TB-500 with KPV for additional anti-inflammatory action.
A short Khavinson-family bioregulator targeting vascular tissue, marketed for cardiovascular and circulatory support.
A Khavinson dipeptide bioregulator marketed for immune regulation and general longevity contexts.